Dolutegravir/Lamivudine/Abacavir
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Dolutegravir/Lamivudine/Abacavir, covering 2020-02-05 to 2020-02-05. Get the full timeline:
Most recent: Clinical Trial Update: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study [Phase 4]